FHI 360, Accelovance collaborate to serve international drug development research efforts

Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in Oncology, Vaccines, and General Medicine and FHI 360, a global nonprofit organization with CRO capabilities focusing on clinical research in developing countries, have entered into a strategic alliance to more comprehensively serve the international drug development research efforts of pharmaceutical, governmental, and nonprofit organizations.

The strategic alliance expands Accelovance's service offering and capabilities in developing countries in Africa, Asia Pacific, and South America, and expands FHI's capabilities and coverage in North America and Europe.

Ted Fitzgerald, FHI 360's Director of Global Research & Services, stated, "FHI 360 is extremely excited to continue to build on an already solid relationship with Accelovance. This opportunity enables both organizations to maximize geographic coverage to deliver cross functional support anywhere in the world to meet the research needs of drug development Sponsors. For FHI 360, leveraging Accelovance's clinical development expertise and resources in the US and Europe is a natural progression in our strong relationship."

Steve Trevisan, Accelovance's CEO added, "As Accelovance continues to grow and receive requests from Sponsor companies to conduct research in developing countries, we've found a great partner in FHI to support these diverse and comprehensive offerings through their well-developed local country expertise, resources, and cultural awareness."

Both CROs have been collaborating on projects in several regions of the world, most notably on a large Phase III Ebola vaccine trial in Sierra Leone. This strategic alliance enables both companies to expand their global footprint and support the full program drug development needs of pharmaceutical, governmental, and nonprofit organizations.

SOURCE Accelovance